Effect of TCN2 776C>G on vitamin B12 cellular availability in end-stage renal disease patients

Kidney International

Volumn 64, Issue 3, 2003, Pages 1095-1100

  Födinger, Manuela ^b   Veitl, Mario ^b   Skoupy, Sonja ^b   Wojcik, Jadwiga ^b   Röhrer, Claudia ^b   Hagen, Wolfgang ^b   Puttinger, Heidi ^b   Hauser, Anna Christine ^b   Vychytil, Andreas ^b   Sunder Plassmann, Gere ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Folate; Hemodialysis; Holo transcobalamin II; MTHFR; Peritoneal dialysis; Polymorphism; TCN2; Total homocysteine; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; TRANSCOBALAMIN II;

ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CONCENTRATION RESPONSE; CREATININE CLEARANCE; DIALYSIS; DREISAVIT; DRUG BIOAVAILABILITY; DRUG TRANSPORT; ERYTHROCYTE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; INTESTINE ABSORPTION; KIDNEY FAILURE; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; TCN2 GENE; TISSUE DISTRIBUTION; VITAMIN METABOLISM;

EID: 12444300784     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00173.x     Document Type: Article

References (25)

1. THE HOMOCYSTEINE STUDIES COLLABORATION: Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 288:2015-2022, 2002
2. FEHR J, DE VECCHI P: Transcobalamin II: A marker for macrophage/histiocyte proliferation. Am J Clin Pathol 84:291-296, 1985
3. NEXO E, CHRISTENSEN AL, PETERSEN TE, FEDOSOV SN: Measurement of transcobalamin by ELISA. Clin Chem 46:1643-1649, 2000
4. CARMEL R: Measuring and interpreting holo-transcobalamin (holotranscobalamin II). Clin Chem 48:407-409, 2002
5. NAMOUR F, OLIVIER JL, ABDELMOUTTALEB I, et al: Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: Relation to transcobalamin and homocysteine concentration in blood. Blood 97:1092-1098, 2001
6. MCCADDON A, BLENNOW K, HUDSON P, et al: Transcobalamin polymorphism and homocysteine. Blood 98:3497-3499, 2001
7. 12 status in healthy older adults. Blood 100:718-720, 2002
8. AFMAN LA, LIEVERS KJ, VAN DER PUT NM, et al: Single nucleotide polymorphisms in the transcobalamin gene: Relationship with transcobalamin concentrations and risk for neural tube defects. Eur J Hum Genet 10:433-438, 2002
9. LIEVERS KJ, AFMAN LA, KLUIJTMANS LA, et al: Polymorphisms in the transcobalamin gene: Association with plasma homocysteine in healthy individuals and vascular disease patients. Clin Chem 48:1383-1389, 2002
10. FÖDINGER M, MANNHALTER C, WÖLFL G, et al: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52:517-523, 1997
11. VYCHYTIL A, FÖDINGER M, WÖLFL G, et al: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 53:1775-1782, 1998
12. HAUSER AC, HAGEN W, REHAK PH, et al: Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. Am J Kidney Dis 37:758-765, 2001
13. SKOUPY S, FÖDINGER M, VEITL M, et al: Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol 13:1331-1337, 2002
14. DIERKES J, DOMRÖSE U, BOSSELMANN KP, et al: Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease. J Ren Nutr 11:67-72, 2001
15. AMERICAN SOCIETY OF HUMAN GENETICS/AMERICAN COLLEGE OF MEDICAL GENETICS TEST AND TECHNOLOGY TRANSFER COMMITTEE WORKING GROUP: ASHG/ACMG statement. Measurement and use of total plasma homocysteine. Am J Hum Genet 63:1541-1543, 1998
16. FROSST P, BLOM HJ, MILOS R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113, 1995
17. CARMEL R, VASIREDDY H, AURANGZEB I, GEORGE K: High serum cobalamin levels in the clinical setting - Clinical associations and holo-transcobalamin changes. Clin Lab Haem 23:365-371, 2001
18. 12 binding by transcobalamin II increases the risk of neural tube defects. QJM 94:159-166, 2001
19. 12 and folate deficiency. A guide for the primary care physician. Arch Intern Med 159:1289-1298, 1999
20. MOELBY L, RASMUSSEN K, RASMUSSEN HH: Serum methylmalonic acid in uraemia. Scand J Clin Lab Invest 52:351-354, 1992
21. MOELBY L, RASMUSSEN K, RING T, NIELSEN G: Relationship between methylmalonic acid and cobalamin in uremia. Kidney Int 57:265-273, 2000
22. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism 48:631-635, 1999
23. BOSE S, SEETHARAM S, SEETHARAM B: Membrane expression and interactions of human transcobalamin II receptor. J Biol Chem 270:8152-8157, 1995
24. 12 in LLC-PK1 renal proximal tubule cells. J Am Soc Nephrol 12:1099-1106, 2001
25. NAMOUR F, GUÉANT JL: Transcobalamin polymorphism, homocysteine, and aging. Blood 98:3499, 2001